Clinical Trial Update: Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a PET response-adapted treatment versus standard treatment in low-risk CD20+ diffuse large B-cell lymphoma (DLBCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: DLBCL | Phase 3 | Status: COMPLETED